Flutamide
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Flutamide: From Prostate Cancer to Benign Reproductive System Neoplasm
One-Sentence Summary
Flutamide is a nonsteroidal antiandrogen historically used in combination hormonal therapy for prostate cancer. Among ten TxGNN-predicted indications for this drug, the most credible genuine repurposing signal points to Benign Reproductive System Neoplasm, supported by 0 clinical trials but 19 related publications (mostly cohort studies on flutamide’s effect on benign prostatic tissue). The remaining nine predictions are either confirmatory of the drug’s known use or unsupported model artifacts — see the supplementary table at the end of this report.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Prostate cancer (androgen-deprivation hormonal therapy) — inferred from the evidence pack’s own mechanistic rationale; formal MOA/indication record is pending DrugBank verification (Data Gap DG002) |
| Predicted New Indication | Benign Reproductive System Neoplasm |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L3 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold (classified internally as “Research Question”) |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not yet available in structured form (Data Gap DG002). Based on the mechanistic rationale attached to this evidence pack, Flutamide is a nonsteroidal antiandrogen that competitively blocks the androgen receptor (AR), inhibiting the effect of testosterone/DHT on androgen-dependent tissue. This is the classic mechanism underlying its established role in prostate cancer hormonal therapy (alone or combined with LHRH agonists/castration).
Benign reproductive system neoplasms — particularly androgen-dependent benign prostatic tissue — share the same underlying dependency on androgen signaling as malignant prostate tissue. Blocking AR activity can shrink androgen-dependent benign prostatic volume, which is mechanistically distinct from, but closely adjacent to, its anticancer use.
Supporting literature (e.g., PMID 1722793, 1989458) directly documents flutamide reducing prostate volume, PSA, and testosterone response in benign prostatic hyperplasia (BPH) patients, and histopathology studies (PMID 17128417, 7526970, 9428430) confirm androgen-blockade-induced changes in benign prostatic tissue. However, this evidence is observational/mechanistic rather than randomized-controlled, and no clinical trial has been registered specifically against the broad “benign reproductive system neoplasm” label.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1722793 | 1991 | Cohort | Journal of Andrology | Flutamide (750 mg/day, 6 months) correlated with reduced prostate volume, PSA, and testosterone in BPH patients (n=43) |
| 17128417 | 2007 | Cohort | Histology and Histopathology | Androgen deprivation/antiandrogens induce histopathologic changes in both benign and malignant prostate tissue |
| 1989458 | 1991 | Cohort | American Journal of Surgical Pathology | LHRH agonist + flutamide combination caused marked atrophy and basal-cell hyperplasia in benign prostatic glands |
| 7526970 | 1994 | Cohort | Cancer | Preoperative estramustine + flutamide induced morphologic/immunohistochemical changes in radical prostatectomy specimens |
| 9428430 | 1997 | Cohort | Urologia Internationalis | Hormonal treatment altered neuroendocrine cell patterns in BPH and prostatic carcinoma tissue |
| 26926093 | 2016 | Review | Pharmacological Research | Review of androgen biotransformation (UGT enzymes) in benign and malignant prostate tissue |
| 12855748 | 2003 | Review | Molecular Endocrinology | Review of sex-steroid receptor signaling in gonadal tumorigenesis (benign and malignant) |
| 9500777 | 1998 | Case Report | American Journal of Surgical Pathology | Pseudomyxoma ovarii-like post-therapeutic alteration described after neoadjuvant leuprolide + flutamide |
| 24615730 | 2014 | Preclinical | The Prostate | Carboxypeptidase-D elevated in prostate cancer; anti-apoptotic activity abolished by combined androgen/prolactin receptor targeting |
| 15816512 | 2005 | Preclinical | Anticancer Research | Established an androgen/AR-antagonist-responsive benign prostate epithelial cell line |
Cytotoxicity
Flutamide is an antineoplastic agent by original indication and drug class (nonsteroidal antiandrogen used in prostate cancer hormonal therapy).
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted (hormonal) therapy — antiandrogen; not a conventional cytotoxic chemotherapy agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Drug Interactions: Flutamide has 285 recorded interactions in the DDI database. Notable Major-level interactions include Dolasetron and Cisapride. Multiple Moderate-level interactions are also recorded, including Famotidine, Loperamide, Bisacodyl, Clarithromycin, Palonosetron, Ondansetron, and several laxative agents (e.g., Lactulose, Polyethylene glycol, Sodium sulfate). A Minor interaction is recorded with Metronidazole.
Key warnings and contraindications are not yet available in structured form; please refer to the package insert for this information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for the “Benign Reproductive System Neoplasm” indication is limited to observational/mechanistic literature (L3, S2 “Research Question”) with zero registered clinical trials directly targeting this indication category. Compounding this, Flutamide is currently not marketed in India (0 registrations), and core drug-level safety data (TFDA/local label warnings and contraindications) remains a Blocking data gap (DG001).
To proceed, the following is needed:
- Confirmed mechanism-of-action and drug classification data via DrugBank API (DG002)
- Local package insert warnings/contraindications (DG001 — currently blocking safety evaluation)
- A prospective or retrospective study specifically evaluating flutamide in a defined benign reproductive neoplasm population (rather than incidental BPH findings from prostate cancer trials)
- Regulatory pathway assessment, since the drug has no existing market authorization in India
Other TxGNN-Predicted Indications (Same Drug, Lower Priority)
This evidence pack scored ten candidate indications for Flutamide. Only two others carry any supporting evidence; the rest are unsupported model artifacts.
| Rank | Disease | Score | Evidence Level | Recommendation | Note | |——|———|——-|—————–|—————–|——| | 1 | Prostate cancer/brain cancer susceptibility | 99.98% | L5 | Hold | Anomalous combined disease label; no biological hypothesis, no trials/literature | | 2 | Fibroma of prostate | 99.98% | L5 | Hold | Theoretical only; no supporting evidence | | 3 | Brenner tumor | 99.98% | L4 | Hold | 2 literature hits, but both are unrelated prostate-cancer papers (embedding noise) | | 4 | Benign reproductive system neoplasm | 99.98% | L3 | Research Question | Primary candidate — see main report above | | 5 | Prostate leiomyoma | 99.98% | L5 | Hold | Theoretical only; no supporting evidence | | 6 | Male reproductive organ cancer | 99.92% | L1 | Proceed with Guardrails | Highest evidence level (50 trials, 20 papers), but overlaps with flutamide’s already-approved prostate cancer use — confirmatory, not a new indication | | 7 | Benign prostate phyllodes tumor | 99.98% | L5 | Hold | No supporting evidence | | 8 | HIV infectious disease | 99.92% | L5 | Hold | No known mechanistic link; no evidence | | 9 | Simian immunodeficiency virus infection | 99.86% | L5 | Hold | Veterinary/model-organism disease; graph-adjacency artifact of HIV entry | | 10 | Feline acquired immunodeficiency syndrome | 99.86% | L5 | Hold | Veterinary indication; not applicable to human drug development |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.